Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?

Nefize Yalin, Allan H Young Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UKCorrespondence: Allan H YoungCentre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yalin N, Young AH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	antidepressant atypical antipsychotic bipolar depression bipolar disorder pharmacotherapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/d1f8190368fe49da9b93c2113314b505
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d1f8190368fe49da9b93c2113314b505
record_format	dspace
spelling	oai:doaj.org-article:d1f8190368fe49da9b93c2113314b5052021-12-02T09:38:12ZPharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?1178-2021https://doaj.org/article/d1f8190368fe49da9b93c2113314b5052020-06-01T00:00:00Zhttps://www.dovepress.com/pharmacological-treatment-of-bipolar-depression-what-are-the-current-a-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Nefize Yalin, Allan H Young Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UKCorrespondence: Allan H YoungCentre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, UKTel +020 78485895Fax +020 78480298, Email allan.young@kcl.ac.ukAbstract: Depression accounts for the predominant burden associated with bipolar disorder. The identification and management of bipolar depression are challenging, since bipolar depression differs from unipolar depression, responding poorly to traditional antidepressants, which may also induce a switch to hypomania/mania, mixed states and/or cause rapid cycling. Current treatment options for bipolar depression are limited and guidelines vary greatly in their recommendations, reflecting gaps and inconsistencies in the current evidence base. Moreover, some treatment options, such as quetiapine and olanzapine–fluoxetine, although clearly efficacious, may be associated with adverse cardiometabolic side effects, which can be detrimental to the long-term physical health and well-being of patients, increasing the likelihood of treatment non-adherence and relapse. Evidence for some more recent therapeutic options, including lurasidone and cariprazine, suggests that patients’ symptoms can be effectively managed without compromising their physical health. In addition, novel agents targeting alternative neurotransmitter pathways and inflammatory processes (such as ketamine and N-acetyl cysteine) are emerging as promising potential options for the treatment of bipolar depression in the future.Keywords: antidepressant, atypical antipsychotic, bipolar depression, bipolar disorder, pharmacotherapyYalin NYoung AHDove Medical Pressarticleantidepressantatypical antipsychoticbipolar depressionbipolar disorderpharmacotherapyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 16, Pp 1459-1472 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	antidepressant atypical antipsychotic bipolar depression bipolar disorder pharmacotherapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	antidepressant atypical antipsychotic bipolar depression bipolar disorder pharmacotherapy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Yalin N Young AH Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
description	Nefize Yalin, Allan H Young Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, London, UKCorrespondence: Allan H YoungCentre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, UKTel +020 78485895Fax +020 78480298, Email allan.young@kcl.ac.ukAbstract: Depression accounts for the predominant burden associated with bipolar disorder. The identification and management of bipolar depression are challenging, since bipolar depression differs from unipolar depression, responding poorly to traditional antidepressants, which may also induce a switch to hypomania/mania, mixed states and/or cause rapid cycling. Current treatment options for bipolar depression are limited and guidelines vary greatly in their recommendations, reflecting gaps and inconsistencies in the current evidence base. Moreover, some treatment options, such as quetiapine and olanzapine–fluoxetine, although clearly efficacious, may be associated with adverse cardiometabolic side effects, which can be detrimental to the long-term physical health and well-being of patients, increasing the likelihood of treatment non-adherence and relapse. Evidence for some more recent therapeutic options, including lurasidone and cariprazine, suggests that patients’ symptoms can be effectively managed without compromising their physical health. In addition, novel agents targeting alternative neurotransmitter pathways and inflammatory processes (such as ketamine and N-acetyl cysteine) are emerging as promising potential options for the treatment of bipolar depression in the future.Keywords: antidepressant, atypical antipsychotic, bipolar depression, bipolar disorder, pharmacotherapy
format	article
author	Yalin N Young AH
author_facet	Yalin N Young AH
author_sort	Yalin N
title	Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
title_short	Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
title_full	Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
title_fullStr	Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
title_full_unstemmed	Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
title_sort	pharmacological treatment of bipolar depression: what are the current and emerging options?
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/d1f8190368fe49da9b93c2113314b505
work_keys_str_mv	AT yalinn pharmacologicaltreatmentofbipolardepressionwhatarethecurrentandemergingoptions AT youngah pharmacologicaltreatmentofbipolardepressionwhatarethecurrentandemergingoptions
_version_	1718398091274485760

Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?

Ejemplares similares